BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $LLY readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07169851-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~LY3537021 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study to Evaluate LY3537021 for the Treatment of Nausea and V
 omiting Caused by Chemotherapy in Adults With Cancer\n\nPrimary completion
  date: 2026-12 (estimated) — month only\, shown on the 1st\nOriginally p
 lanned: 2026-09 (+3.0 months)\nPhase 2 · Oncology · Nausea\, Vomiting\, 
 Drug-Related Side Effects and Adverse Reactions\nEnrollment: 204 · Sites:
  67\n\nPrimary completion = last participant's primary-endpoint data colle
 cted\; topline results usually follow weeks to months later. Sponsor-repor
 ted\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/
 radar.html?nct=NCT07169851\nhttps://clinicaltrials.gov/study/NCT07169851
URL:https://datacutoff.com/radar.html?nct=NCT07169851
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413706-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~Abemaciclib readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide
  Monotherapy in Children and Young Adults With High-grade Glioma Following
  Radiotherapy\n\nPrimary completion date: 2027-02 (estimated) — month on
 ly\, shown on the 1st\nOriginally planned: 2027-07 (-4.9 months)\nPhase 2 
 · Oncology · Glioma\nEnrollment: 45 · Sites: 37\n\nPrimary completion =
  last participant's primary-endpoint data collected\; topline results usua
 lly follow weeks to months later. Sponsor-reported\, often an estimate. No
 t investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06413706\
 nhttps://clinicaltrials.gov/study/NCT06413706
URL:https://datacutoff.com/radar.html?nct=NCT06413706
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672549-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~ADVANCE readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Platform Trial for Pediatric Participants With Obesity or Ove
 rweight (LY900040)\n\nPrimary completion date: 2027-02 (estimated) — mon
 th only\, shown on the 1st\nPhase 3 · Cardio-Met · Obesity\, Overweight\
 nEnrollment: 125 · Sites: 117\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://datacutoff.com/radar.html?nct=NCT06672549\nhttps://clinicaltri
 als.gov/study/NCT06672549
URL:https://datacutoff.com/radar.html?nct=NCT06672549
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223840-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~RENEW-Smk-1 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Brenipatide in Adults Who Quit Smoking Cigarettes an
 d Want to Avoid Relapse\n\nPrimary completion date: 2027-02 (estimated) 
 — month only\, shown on the 1st\nPhase 2 · Other · Smoking\nEnrollment
 : 222 · Sites: 29\n\nPrimary completion = last participant's primary-endp
 oint data collected\; topline results usually follow weeks to months later
 . Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://
 datacutoff.com/radar.html?nct=NCT07223840\nhttps://clinicaltrials.gov/stud
 y/NCT07223840
URL:https://datacutoff.com/radar.html?nct=NCT07223840
CATEGORIES:Other,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215559-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~Macupatide readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Macupatide (LY3532226) and Eloralintide (LY3841136)\
 , Alone or in Combination\, in Adults With Obesity or Overweight and With 
 Type 2 Diabetes\n\nPrimary completion date: 2027-03 (estimated) — month 
 only\, shown on the 1st\nPhase 2 · Cardio-Met · Obesity\, Overweight\, D
 iabetes Mellitus\, Type 2\nEnrollment: 200 · Sites: 42\n\nPrimary complet
 ion = last participant's primary-endpoint data collected\; topline results
  usually follow weeks to months later. Sponsor-reported\, often an estimat
 e. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0721
 5559\nhttps://clinicaltrials.gov/study/NCT07215559
URL:https://datacutoff.com/radar.html?nct=NCT07215559
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269210-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~SOLARIS-1 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Solbinsiran (LY3561774) in Participants With Severe 
 Hypertriglyceridemia\n\nPrimary completion date: 2027-03 (estimated) — m
 onth only\, shown on the 1st\nPhase 2 · Cardio-Met · Severe Hypertriglyc
 eridemia\nEnrollment: 60 · Sites: 41\n\nPrimary completion = last partici
 pant's primary-endpoint data collected\; topline results usually follow we
 eks to months later. Sponsor-reported\, often an estimate. Not investment 
 advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07269210\nhttps://clin
 icaltrials.gov/study/NCT07269210
URL:https://datacutoff.com/radar.html?nct=NCT07269210
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05986292-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:~CPMP readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Master Protocol Study (LY900028) of Multiple Intervention-Spe
 cific-Appendices (ISAs) in Participants With Chronic Pain\n\nPrimary compl
 etion date: 2027-04 (estimated) — month only\, shown on the 1st\nPhase 2
  · Cardio-Met · Osteoarthritis\, Knee\, Diabetic Neuropathic Pain\, Chro
 nic Low-back Pain\nEnrollment: 10000 · Sites: 64\n\nPrimary completion = 
 last participant's primary-endpoint data collected\; topline results usual
 ly follow weeks to months later. Sponsor-reported\, often an estimate. Not
  investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05986292\n
 https://clinicaltrials.gov/study/NCT05986292
URL:https://datacutoff.com/radar.html?nct=NCT05986292
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641504-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:~BP07 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in 
 Participants With Chronic Low Back Pain\n\nPrimary completion date: 2027-0
 4 (estimated) — month only\, shown on the 1st\nPhase 2 · Neuro · Chron
 ic Pain\, Low Back Pain\nEnrollment: 150 · Sites: 36\n\nPrimary completio
 n = last participant's primary-endpoint data collected\; topline results u
 sually follow weeks to months later. Sponsor-reported\, often an estimate.
  Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT076415
 04\nhttps://clinicaltrials.gov/study/NCT07641504
URL:https://datacutoff.com/radar.html?nct=NCT07641504
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641517-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:~OA07 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in 
 Participants With Osteoarthritis Pain\n\nPrimary completion date: 2027-04 
 (estimated) — month only\, shown on the 1st\nPhase 2 · Neuro · Osteoar
 thritis\, Knee\, Chronic Pain\nEnrollment: 150 · Sites: 36\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT
 07641517\nhttps://clinicaltrials.gov/study/NCT07641517
URL:https://datacutoff.com/radar.html?nct=NCT07641517
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05999994-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~CAMPFIRE readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Master Protocol (LY900023) That Includes Several Clinical Tri
 als of Drugs for Children and Young Adults With Cancer\n\nPrimary completi
 on date: 2027-05 (estimated) — month only\, shown on the 1st\nOriginally
  planned: 2026-05-01 (+12.0 months)\nPhase 2 · Oncology · Neoplasms\, Ch
 ild\, Adolescent\nEnrollment: 105 · Sites: 72\n\nPrimary completion = las
 t participant's primary-endpoint data collected\; topline results usually 
 follow weeks to months later. Sponsor-reported\, often an estimate. Not in
 vestment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05999994\nhtt
 ps://clinicaltrials.gov/study/NCT05999994
URL:https://datacutoff.com/radar.html?nct=NCT05999994
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06338995-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~LY3650150 readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Lebrikizumab (LY3650150) in Participants With Chroni
 c Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids 
 (CONTRAST-NP)\n\nPrimary completion date: 2027-05 (estimated) — month on
 ly\, shown on the 1st\nOriginally planned: 2025-11-22 (+17.2 months)\nPhas
 e 3 · Other · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)\nEnrollm
 ent: 510 · Sites: 202\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://datacutoff.com/radar.html?nct=NCT06338995\nhttps://clinicaltrials.gov/
 study/NCT06338995
URL:https://datacutoff.com/radar.html?nct=NCT06338995
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897475-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~LY3457263 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of LY3457263 Compared With Placebo in Participants With
  Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide\n\nPrimary
  completion date: 2027-05 (estimated) — month only\, shown on the 1st\nO
 riginally planned: 2026-12 (+5.0 months)\nPhase 2 · Cardio-Met · Type 2 
 Diabetes\nEnrollment: 200 · Sites: 60\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06897475\nhttps://cli
 nicaltrials.gov/study/NCT06897475
URL:https://datacutoff.com/radar.html?nct=NCT06897475
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07186101-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~TOPAZ-UC readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults
  With Moderately to Severely Active Ulcerative Colitis:\n\nPrimary complet
 ion date: 2027-05 (estimated) — month only\, shown on the 1st\nPhase 2 
 · GI·Renal·Heme · Ulcerative Colitis\nEnrollment: 252 · Sites: 147\n\
 nPrimary completion = last participant's primary-endpoint data collected\;
  topline results usually follow weeks to months later. Sponsor-reported\, 
 often an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.
 html?nct=NCT07186101\nhttps://clinicaltrials.gov/study/NCT07186101
URL:https://datacutoff.com/radar.html?nct=NCT07186101
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07533019-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~LY4005130 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of LY4005130 in Adult Participants With Non-Segmental V
 itiligo\n\nPrimary completion date: 2027-05 (estimated) — month only\, s
 hown on the 1st\nPhase 2 · Immuno · Vitiligo\, Non-Segmental Vitiligo (N
 SV)\nEnrollment: 66 · Sites: 35\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://datacutoff.com/radar.html?nct=NCT07533019\nhttps://clinicalt
 rials.gov/study/NCT07533019
URL:https://datacutoff.com/radar.html?nct=NCT07533019
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613307-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~ACHIEVE-RAM readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Orforglipron (LY3502970) in Participants With Type 2
  Diabetes Who Observe Ramadan Fasting\n\nPrimary completion date: 2027-05 
 (estimated) — month only\, shown on the 1st\nPhase 3 · Cardio-Met · Di
 abetes Mellitus\, Type 2\, Diabetes Melletus\, Glucose Metabolism Disorder
 s\nEnrollment: 130 · Sites: 40\n\nPrimary completion = last participant's
  primary-endpoint data collected\; topline results usually follow weeks to
  months later. Sponsor-reported\, often an estimate. Not investment advice
 .\n\nhttps://datacutoff.com/radar.html?nct=NCT07613307\nhttps://clinicaltr
 ials.gov/study/NCT07613307
URL:https://datacutoff.com/radar.html?nct=NCT07613307
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783802-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~CLARITY-CRP readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Clazakizumab (LY5724886) in Adults With Elevated hsC
 RP and at Increased Risk for Cardiovascular Event\n\nPrimary completion da
 te: 2027-05 (estimated) — month only\, shown on the 1st\nPhase 2 · Card
 io-Met · Atherosclerosis\, Cardiovascular Disease\, Obesity\nEnrollment: 
 120 · Sites: 46\n\nPrimary completion = last participant's primary-endpoi
 nt data collected\; topline results usually follow weeks to months later. 
 Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://da
 tacutoff.com/radar.html?nct=NCT07783802\nhttps://clinicaltrials.gov/study/
 NCT07783802
URL:https://datacutoff.com/radar.html?nct=NCT07783802
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232719-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~TRIUMPH-8 readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Retatrutide (LY3437943) in Participants With Obesity
  or Overweight\n\nPrimary completion date: 2027-06 (estimated) — month o
 nly\, shown on the 1st\nPhase 3 · Cardio-Met · Obesity\, Overweight\nEnr
 ollment: 250 · Sites: 31\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://datacutoff.com/radar.html?nct=NCT07232719\nhttps://clinicaltrials.g
 ov/study/NCT07232719
URL:https://datacutoff.com/radar.html?nct=NCT07232719
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483073-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~Mirikizumab - Intravenous (IV) readout (P2) · Eli Lilly and Compa
 ny $LLY
DESCRIPTION:A Master Protocol (IIBD): A Study of Multiple Drugs in Adults W
 ith Ulcerative Colitis or Crohn's Disease\n\nPrimary completion date: 2027
 -06 (estimated) — month only\, shown on the 1st\nPhase 2 · GI·Renal·H
 eme · Colitis\, Ulcerative\, Crohn Disease\nEnrollment: 60 · Sites: 71\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT07483073\nhttps://clinicaltrials.gov/study/NCT07483073
URL:https://datacutoff.com/radar.html?nct=NCT07483073
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483099-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~LY4395089 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of LY4395089 and Mirikizumab (LY3074828) Given Together
  and Mirikizumab (Alone) in Adults With Crohn's Disease\n\nPrimary complet
 ion date: 2027-06 (estimated) — month only\, shown on the 1st\nPhase 2 
 · GI·Renal·Heme · Crohn Disease\nEnrollment: 60 · Sites: 71\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nc
 t=NCT07483099\nhttps://clinicaltrials.gov/study/NCT07483099
URL:https://datacutoff.com/radar.html?nct=NCT07483099
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07533006-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~LY4005130 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of LY4005130 in Adult Participants With Severe Alopecia
  Areata (Hair Loss)\n\nPrimary completion date: 2027-06 (estimated) — mo
 nth only\, shown on the 1st\nPhase 2 · Immuno · Alopecia Areata\nEnrollm
 ent: 65 · Sites: 30\n\nPrimary completion = last participant's primary-en
 dpoint data collected\; topline results usually follow weeks to months lat
 er. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:
 //datacutoff.com/radar.html?nct=NCT07533006\nhttps://clinicaltrials.gov/st
 udy/NCT07533006
URL:https://datacutoff.com/radar.html?nct=NCT07533006
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285018-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~NP07 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in 
 Participants With Diabetic Peripheral Neuropathic Pain\n\nPrimary completi
 on date: 2027-07 (estimated) — month only\, shown on the 1st\nPhase 2 ·
  Cardio-Met · Diabetic Peripheral Neuropathic Pain\nEnrollment: 150 · Si
 tes: 36\n\nPrimary completion = last participant's primary-endpoint data c
 ollected\; topline results usually follow weeks to months later. Sponsor-r
 eported\, often an estimate. Not investment advice.\n\nhttps://datacutoff.
 com/radar.html?nct=NCT07285018\nhttps://clinicaltrials.gov/study/NCT072850
 18
URL:https://datacutoff.com/radar.html?nct=NCT07285018
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545772-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~RENEW-IBS-C readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Brenipatide (LY3537031) in Participants With Irritab
 le Bowel Syndrome-Constipation (IBS-C)\n\nPrimary completion date: 2027-07
  (estimated) — month only\, shown on the 1st\nPhase 2 · GI·Renal·Heme
  · Irritable Bowel Syndrome\, Constipation\nEnrollment: 342 · Sites: 70\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://datacutoff.com/rada
 r.html?nct=NCT07545772\nhttps://clinicaltrials.gov/study/NCT07545772
URL:https://datacutoff.com/radar.html?nct=NCT07545772
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972459-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~Orforglipron readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Orforglipron (LY3502970) in Participants With Obesit
 y or Overweight and at Least One Weight-Related Comorbidity\n\nPrimary com
 pletion date: 2027-08 (estimated) — month only\, shown on the 1st\nOrigi
 nally planned: 2027-01 (+7.0 months)\nPhase 3 · Cardio-Met · Obesity\, O
 verweight\nEnrollment: 800 · Sites: 80\n\nPrimary completion = last parti
 cipant's primary-endpoint data collected\; topline results usually follow 
 weeks to months later. Sponsor-reported\, often an estimate. Not investmen
 t advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06972459\nhttps://cl
 inicaltrials.gov/study/NCT06972459
URL:https://datacutoff.com/radar.html?nct=NCT06972459
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972472-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~Orforglipron readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Orforglipron (LY3502970) in Participants With Obesit
 y or Overweight and Type 2 Diabetes\n\nPrimary completion date: 2027-08 (e
 stimated) — month only\, shown on the 1st\nOriginally planned: 2027-01 (
 +7.0 months)\nPhase 3 · Cardio-Met · Obesity\, Overweight\, Type 2 Diabe
 tes\nEnrollment: 600 · Sites: 80\n\nPrimary completion = last participant
 's primary-endpoint data collected\; topline results usually follow weeks 
 to months later. Sponsor-reported\, often an estimate. Not investment advi
 ce.\n\nhttps://datacutoff.com/radar.html?nct=NCT06972472\nhttps://clinical
 trials.gov/study/NCT06972472
URL:https://datacutoff.com/radar.html?nct=NCT06972472
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993792-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~Orforglipron readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Master Protocol for Orforglipron (LY3502970) in Participants 
 With Obesity or Overweight With and Without Type 2 Diabetes\n\nPrimary com
 pletion date: 2027-08 (estimated) — month only\, shown on the 1st\nOrigi
 nally planned: 2027-01 (+7.0 months)\nPhase 3 · Cardio-Met · Obesity\, O
 verweight\, Type 2 Diabetes\nEnrollment: 1400 · Sites: 80\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0
 6993792\nhttps://clinicaltrials.gov/study/NCT06993792
URL:https://datacutoff.com/radar.html?nct=NCT06993792
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~LY3305677 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Master Protocol Study (LY900038) of Multiple Intervention-Spe
 cific-Appendices (ISAs) in Adult Participants With Obesity or Overweight\n
 \nPrimary completion date: 2027-09 (estimated) — month only\, shown on t
 he 1st\nOriginally planned: 2024-11-29 (+33.0 months)\nPhase 2 · Cardio-M
 et · Obesity\, Overweight\nEnrollment: 1481 · Sites: 57\n\nPrimary compl
 etion = last participant's primary-endpoint data collected\; topline resul
 ts usually follow weeks to months later. Sponsor-reported\, often an estim
 ate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06
 143956\nhttps://clinicaltrials.gov/study/NCT06143956
URL:https://datacutoff.com/radar.html?nct=NCT06143956
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948422-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~Orforglipron readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Master Protocol for Orforglipron (LY3502970) in Participants 
 With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screenin
 g)\n\nPrimary completion date: 2027-09 (estimated) — month only\, shown 
 on the 1st\nPhase 3 · Cardio-Met · Hypertension\nEnrollment: 974 · Site
 s: 100\n\nPrimary completion = last participant's primary-endpoint data co
 llected\; topline results usually follow weeks to months later. Sponsor-re
 ported\, often an estimate. Not investment advice.\n\nhttps://datacutoff.c
 om/radar.html?nct=NCT06948422\nhttps://clinicaltrials.gov/study/NCT0694842
 2
URL:https://datacutoff.com/radar.html?nct=NCT06948422
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948435-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~Orforglipron readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Master Protocol Study of Orforglipron (LY3502970) in Particip
 ants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL
 1\n\nPrimary completion date: 2027-09 (estimated) — month only\, shown o
 n the 1st\nPhase 3 · Cardio-Met · Hypertension\, Overweight or Obesity\n
 Enrollment: 487 · Sites: 99\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT06948435\nhttps://clinicaltrial
 s.gov/study/NCT06948435
URL:https://datacutoff.com/radar.html?nct=NCT06948435
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952530-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~Orforglipron readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Master Protocol Study of Orforglipron (LY3502970) in Particip
 ants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL
 2\n\nPrimary completion date: 2027-09 (estimated) — month only\, shown o
 n the 1st\nPhase 3 · Cardio-Met · Hypertension\nEnrollment: 487 · Sites
 : 99\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com
 /radar.html?nct=NCT06952530\nhttps://clinicaltrials.gov/study/NCT06952530
URL:https://datacutoff.com/radar.html?nct=NCT06952530
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07035093-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~TRIUMPH-7 readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Retatrutide (LY3437943) in Participants Who Have Obe
 sity or Overweight and Chronic Low Back Pain\n\nPrimary completion date: 2
 027-09 (estimated) — month only\, shown on the 1st\nPhase 3 · Cardio-Me
 t · Obesity\, Overweight\, Chronic Low Back Pain (CLBP)\nEnrollment: 586 
 · Sites: 40\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://datacu
 toff.com/radar.html?nct=NCT07035093\nhttps://clinicaltrials.gov/study/NCT0
 7035093
URL:https://datacutoff.com/radar.html?nct=NCT07035093
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545759-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~RENEW-IBS-D readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Brenipatide (LY3537031) in Participants With Irritab
 le Bowel Syndrome-Diarrhea (IBS-D)\n\nPrimary completion date: 2027-09 (es
 timated) — month only\, shown on the 1st\nPhase 2 · GI·Renal·Heme · 
 Irritable Bowel Syndrome\, Diarrhea\nEnrollment: 531 · Sites: 89\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?n
 ct=NCT07545759\nhttps://clinicaltrials.gov/study/NCT07545759
URL:https://datacutoff.com/radar.html?nct=NCT07545759
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589608-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~Macupatide readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study to Investigate Weight Management With Macupatide and El
 oralintide\, Alone or in Combination\, in Adult Participants With Obesity 
 or Overweight\n\nPrimary completion date: 2027-09 (estimated) — month on
 ly\, shown on the 1st\nPhase 2 · Cardio-Met · Overweight\, Obesity\nEnro
 llment: 400 · Sites: 40\n\nPrimary completion = last participant's primar
 y-endpoint data collected\; topline results usually follow weeks to months
  later. Sponsor-reported\, often an estimate. Not investment advice.\n\nht
 tps://datacutoff.com/radar.html?nct=NCT07589608\nhttps://clinicaltrials.go
 v/study/NCT07589608
URL:https://datacutoff.com/radar.html?nct=NCT07589608
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05254743-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~BRUIN-CLL-314 readout (P3) · Loxo Oncology\, Inc. $LLY
DESCRIPTION:A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Partici
 pants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (
 SLL)\n\nPrimary completion date: 2027-10 (estimated) — month only\, show
 n on the 1st\nOriginally planned: 2028-03-01 (-5.0 months)\nPhase 3 · Onc
 ology · Chronic Lymphocytic Leukemia\, Leukemia\, Lymphocytic\, Leukemia\
 , B-cell\nEnrollment: 737 · Sites: 143\n\nPrimary completion = last parti
 cipant's primary-endpoint data collected\; topline results usually follow 
 weeks to months later. Sponsor-reported\, often an estimate. Not investmen
 t advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05254743\nhttps://cl
 inicaltrials.gov/study/NCT05254743
URL:https://datacutoff.com/radar.html?nct=NCT05254743
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05514054-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~EMBER-4 readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Imlunestrant Versus Standard Endocrine Therapy in Pa
 rticipants With Early Breast Cancer\n\nPrimary completion date: 2027-10 (e
 stimated) — month only\, shown on the 1st\nPhase 3 · Oncology · Breast
  Neoplasms\nEnrollment: 8000 · Sites: 672\n\nPrimary completion = last pa
 rticipant's primary-endpoint data collected\; topline results usually foll
 ow weeks to months later. Sponsor-reported\, often an estimate. Not invest
 ment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05514054\nhttps:/
 /clinicaltrials.gov/study/NCT05514054
URL:https://datacutoff.com/radar.html?nct=NCT05514054
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05556512-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~SURMOUNT-MMO readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Tirzepatide (LY3298176) on the Reduction on Morbidit
 y and Mortality in Adults With Obesity\n\nPrimary completion date: 2027-10
  (estimated) — month only\, shown on the 1st\nPhase 3 · Cardio-Met · O
 besity\, Overweight\nEnrollment: 15374 · Sites: 672\n\nPrimary completion
  = last participant's primary-endpoint data collected\; topline results us
 ually follow weeks to months later. Sponsor-reported\, often an estimate. 
 Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0555651
 2\nhttps://clinicaltrials.gov/study/NCT05556512
URL:https://datacutoff.com/radar.html?nct=NCT05556512
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439277-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~Tirzepatide readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Tirzepatide in Adolescents With Obesity and Weight-R
 elated Comorbidities (SURMOUNT-ADOLESCENTS-2)\n\nPrimary completion date: 
 2027-10 (estimated) — month only\, shown on the 1st\nOriginally planned:
  2027-05 (+5.0 months)\nPhase 3 · Cardio-Met · Obesity\, Weight Gain\nEn
 rollment: 300 · Sites: 69\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://datacutoff.com/radar.html?nct=NCT06439277\nhttps://clinicaltrials.
 gov/study/NCT06439277
URL:https://datacutoff.com/radar.html?nct=NCT06439277
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04662255-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~BRUIN-MCL-321 readout (P3) · Loxo Oncology\, Inc. $LLY
DESCRIPTION:Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor D
 rugs in Patients With Mantle Cell Lymphoma (MCL)\n\nPrimary completion dat
 e: 2027-11 (estimated) — month only\, shown on the 1st\nOriginally plann
 ed: 2024-08 (+39.0 months)\nPhase 3 · Oncology · Lymphoma\, Mantle-Cell\
 nEnrollment: 500 · Sites: 189\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://datacutoff.com/radar.html?nct=NCT04662255\nhttps://clinicaltri
 als.gov/study/NCT04662255
URL:https://datacutoff.com/radar.html?nct=NCT04662255
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026866-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~Donanemab readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Donanemab (LY3002813) Study in Participants With Preclinical 
 Alzheimer's Disease (TRAILBLAZER-ALZ 3)\n\nPrimary completion date: 2027-1
 1 (estimated) — month only\, shown on the 1st\nOriginally planned: 2027-
 09-25 (+1.2 months)\nPhase 3 · Neuro · Alzheimer Disease\nEnrollment: 29
 96 · Sites: 216\n\nPrimary completion = last participant's primary-endpoi
 nt data collected\; topline results usually follow weeks to months later. 
 Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://da
 tacutoff.com/radar.html?nct=NCT05026866\nhttps://clinicaltrials.gov/study/
 NCT05026866
URL:https://datacutoff.com/radar.html?nct=NCT05026866
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06119581-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~SUNRAY-01 readout (P3) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab 
 With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant No
 n-small Cell Lung Cancer\n\nPrimary completion date: 2027-11 (estimated) 
 — month only\, shown on the 1st\nOriginally planned: 2026-10-01 (+13.0 m
 onths)\nPhase 3 · Oncology · Carcinoma\, Non-Small-Cell Lung\, Neoplasm 
 Metastasis\nEnrollment: 1264 · Sites: 415\n\nPrimary completion = last pa
 rticipant's primary-endpoint data collected\; topline results usually foll
 ow weeks to months later. Sponsor-reported\, often an estimate. Not invest
 ment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06119581\nhttps:/
 /clinicaltrials.gov/study/NCT06119581
URL:https://datacutoff.com/radar.html?nct=NCT06119581
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286175-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~Brenipatide readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Brenipatide in Adult Participants With Bipolar Disor
 der (RENEW-Bipolar-1)\n\nPrimary completion date: 2027-11 (estimated) — 
 month only\, shown on the 1st\nPhase 2 · Neuro · Bipolar Disorder\nEnrol
 lment: 400 · Sites: 87\n\nPrimary completion = last participant's primary
 -endpoint data collected\; topline results usually follow weeks to months 
 later. Sponsor-reported\, often an estimate. Not investment advice.\n\nhtt
 ps://datacutoff.com/radar.html?nct=NCT07286175\nhttps://clinicaltrials.gov
 /study/NCT07286175
URL:https://datacutoff.com/radar.html?nct=NCT07286175
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410507-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~RENEW-Scz-1 readout (P2) · Eli Lilly and Company $LLY
DESCRIPTION:A Study of Brenipatide in Adult Participants With Schizophrenia
 \n\nPrimary completion date: 2027-11 (estimated) — month only\, shown on
  the 1st\nPhase 2 · Neuro · Schizophrenia\nEnrollment: 450 · Sites: 101
 \n\nPrimary completion = last participant's primary-endpoint data collecte
 d\; topline results usually follow weeks to months later. Sponsor-reported
 \, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/rad
 ar.html?nct=NCT07410507\nhttps://clinicaltrials.gov/study/NCT07410507
URL:https://datacutoff.com/radar.html?nct=NCT07410507
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
